VULVAR CANCER

This study tests whether combining two drugs—atezolizumab (an immunotherapy) and tivozanib (a targeted therapy)—can shrink tumors in cancers that usually don't respond to immunotherapy alone. About 29 adults with advanced bile duct, gallbladder, breast, neuroendocrine, ovarian, p…

This study tests a treatment called electrochemotherapy for women whose vulvar cancer has come back. It combines a chemotherapy drug with mild electric pulses to help the drug enter cancer cells more effectively. The goal is to shrink tumors and reduce the need for major surgery,…

This study tests whether the immunotherapy drug dostarlimab, alone or combined with bevacizumab, works better than standard chemotherapy for women with recurrent clear cell carcinoma of the ovary, uterus, cervix, vagina, or vulva. About 198 participants will be randomly assigned …

This early-phase study tests whether a single dose of a patient's own genetically modified immune cells (E7 TCR-T cells) can shrink or eliminate tumors in people with advanced HPV-related cancers before they receive standard treatments like radiation or surgery. About 15 particip…

This study tests a drug called belzutifan in people with a rare, hard-to-treat type of gynecologic cancer called clear cell carcinoma. The goal is to see if the drug can shrink tumors or stop them from growing. About 32 participants will receive the drug, and researchers will mon…

This study aims to see if customizing surgery for vulvar cancer based on whether the cancer is linked to HPV or a p53 gene mutation leads to better results. About 249 women with early-stage vulvar squamous cell carcinoma will receive surgery guided by these markers. The goal is t…

This study tests whether using MRI instead of CT to guide brachytherapy (internal radiation) can better target tumors and reduce radiation exposure to nearby organs like the bladder and rectum. About 54 adults with cervical, uterine, vaginal, vulvar, or bladder cancer will receiv…

This study looks at how well the drug T-DXd works for adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good alternatives. About 100 people will take T-DXd as part of their regular care, and researchers will track tumor shrinkage …

This study compares a dye called ICG alone against the standard two-method approach (ICG plus a radioactive tracer) to find cancer in lymph nodes of women with early vulvar cancer. About 58 women will take part. If ICG alone works just as well, it could simplify surgery and reduc…

This study looks at whether the things people buy at stores—like pain relievers or digestive aids—could be early warning signs of cancer. Researchers will compare the shopping habits of 2900 people, some diagnosed with cancer and some not, to see if certain purchases happen more …

This study looks at whether adding pelvic floor physical therapy before standard radiation treatment can help reduce pain and sexual problems in women with cervical, vaginal, vulvar, uterine, or anal cancer. About 20 participants will receive education on using a vaginal dilator …

This study tests whether Reiki, a gentle touch therapy, can reduce anxiety and pain in people receiving brachytherapy for gynecologic cancers like endometrial or cervical cancer. About 70 participants will be randomly assigned to receive either Reiki or usual care during their tr…

This study tests a personalized physical activity program for women over 60 with gynecologic cancers who are receiving chemotherapy or other systemic treatments. The program includes a wearable activity tracker and a smartphone app, plus optional features like an exercise partner…

This study looks at new ways to detect if vulva cancer returns after treatment. Researchers will ask women to complete regular surveys about their symptoms and will also test their blood for tumor DNA. The goal is to see if these methods can find a recurrence earlier than standar…

This study looks at whether changes in a blood marker called CRP can help predict how well immunotherapy works in women with advanced gynecologic cancers (cervical, endometrial, ovarian, or vulvar). Researchers will track CRP levels in 120 women receiving immunotherapy plus chemo…